SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay.

ABSTRACT: Serosurveillance studies are critical for estimating SARS-CoV-2 transmission and immunity, but interpretation of results is currently limited by poorly defined variability in the performance of antibody assays to detect seroreactivity over time in individuals with different clinical presentations. We measured longitudinal antibody responses to SARS-CoV-2 in plasma samples from a diverse cohort of 128 individuals over 160 days using 14 binding and neutralization assays. For all assays, we found a consistent and strong effect of disease severity on antibody magnitude, with fever, cough, hospitalization, and oxygen requirement explaining much of this variation. We found that binding assays measuring responses to spike protein had consistently higher correlation with neutralization than those

SUBMITTER: Peluso MJ 

PROVIDER: S-EPMC7941652 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature